mRNA-4359 alone or in combination with pembrolizumab dependent on which arm the participant is assigned. mRNA-4359 dosing: mRNA-4359 will be given at the study site by injection into shoulder or thigh muscle (intramuscular [IM] injection) once every 3 weeks (Day 1 of every cycle). Up to 9 doses of mRNA-4359 will be given in this study, over an approximately 6-month period. Pembrolizumab dosing: If taking pembrolizumab in combination with mRNA-4539, pembrolizumab will be given at the study site by infusion into ...

GO TO STUDY

The primary objective is to determine whether there is a cyclical component to hypercortisolaemia in all patients diagnosed with endogenous Cushing’s syndrome. The secondary objective is to study post-operative CS patients who have features of CS recurrence and also to study patients with strong clinical suspicion for CS but no test is confirming the diagnosis. Study question in this group: how long should patients be monitored before it can be concluded that the patient does not have CS.

GO TO STUDY

The liver plays a key role in producing the proteins involved in blood clotting (haemostasis), both proteins promoting clotting (pro-coagulants) and those preventing clotting (anti-coagulants). It also has a role in removing these proteins from the circulation. Patients with liver disease have complex changes in haemostasis, which is overall ‘rebalanced’. When patients with liver disease are sick, and admitted to hospital, this rebalanced haemostasis is thought to be more unstable. These patients are at high risk of both bleeding and ...

GO TO STUDY

This is a single stage,single arm phase II,open,label,multi centre trial of patients with HER2 positive GOA who are ctDNA positive following neoadjuvant chemotherapy and surgery. HER2 positive will be defined as IHC3+ or IHC2+/ISH+ positive on diagnostic biopsy or resection specimen. ctDNA result will be determined using the Natera Signatera assay. All patients will be treated with trastuzumab deruxtecan at a dose of 6.4 mg/kg intravenously every 21 days for 6 months. If required patients may dose reduce to 5.4 ...

GO TO STUDY

This project aims to create a sustainable, UK-wide, collaborative research network building a bioresource of skin cancer samples with the relevant governance and procedures to collect and retain biomaterial and linked clinical data to support research. The initial project is a study of gene expression and immunological mechanisms in high-risk cutaneous squamous cell carcinomas (cSCC) involving state-of-the-art molecular analyses and bioinformatics. These data will initiate a molecular 'Atlas' for this poorly understood, yet very common, skin cancer. The Biobank will ...

GO TO STUDY

The PROTECT-HF trial, funded by the British Heart Foundation, will compare two different pacing approaches for treating patients with slow heart rates. In it we will compare the standard approach for pacing, right ventricular pacing, with a new form of pacing, physiological pacing. With right ventricular pacing the pacemaker lead is positioned on the heart muscle in the right ventricle (the chamber of the heart which pumps blood to the lungs). This method is very effective at treating slow heart ...

GO TO STUDY

IELSG48 is a Phase III,interventional,multicenter,open label,randomized study to evaluate whether treatment with zanubrutinib in combination with rituximab will result in an improvement in PFS compared to treatment with rituximab in patients with previously untreated SMZL. Approximately 120 subjects will be randomized in a 1:1 ratio to receive zanubrutinib and rituximab Treatment Arm A) or rituximab (Treatment Arm B). The study will include a Screening Phase,a Treatment Phase,and a Follow-Up Phase. Subjects with investigator-confirmed progressive disease according to the Lugano 2014 criteria ...

GO TO STUDY

Degenerative (wear and tear arthritis of the spine) Cervical (concerning the neck) Myelopathy (injury to the spinal cord), DCM, is the most common spinal cord disorder of adulthood. In DCM, arthritis of the spine causes compression of the spinal cord. The symptoms of DCM are often mistaken for natural consequences of ageing, including numb and clumsy hands, loss of coordination, imbalance, bladder and bowel problems. The weakness can progress to severe paralysis. Every year approximately 4 individuals in 100,000 undergo ...

GO TO STUDY

Sodium bicarbonate is widely,but not universally,used to treat metabolic acidosis in very preterm babies but the evidence underpinning its use is poor. The BASE trial aims to answer the question,‘In very preterm babies with metabolic acidosis,does giving them sodium bicarbonate or not impact on their health and development in the short and long term?’ The primary objective of the BASE trial is to evaluate the effect of sodium bicarbonate on survival to discharge from neonatal care without major morbidity. In this randomised ...

GO TO STUDY

REGN4018 and cemiplimab are the study drugs under investigation for the treatment of ovarian cancer. They are both investigational drugs, meaning they have not received approval from health authorities for the treatment of ovarian cancer. The purpose of this study is to learn about the safety of REGN4018 and to find out what dose of REGN4018 can be given alone or with cemiplimab to patients with ovarian cancer, without causing too many side effects. The study will also look at ...

GO TO STUDY